

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

U-87MG ATCC

RRID:CVCL_0022

Type: Cell Line

Proper Citation

RRID:CVCL_0022

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0022

Proper Citation: RRID:CVCL_0022

Description: Cell line U-87MG ATCC is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: [PMID:327080](#), [PMID:450131](#), [PMID:833871](#), [PMID:3518877](#), [PMID:7459858](#), [PMID:7763724](#), [PMID:8069455](#), [PMID:9090379](#), [PMID:9230885](#), [PMID:9842975](#), [PMID:10074188](#), [PMID:10402232](#), [PMID:10416987](#), [PMID:10560660](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:11966317](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:14961077](#), [PMID:16232199](#), [PMID:16697959](#), [PMID:17595512](#), [PMID:19365568](#), [PMID:19435942](#), [PMID:20126413](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20587068](#), [PMID:20593219](#), [PMID:21406405](#), [PMID:22282976](#), [PMID:22460905](#), [PMID:22570425](#), [PMID:23325432](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26496030](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27412690](#), [PMID:27582061](#), [PMID:27894925](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:33385022](#)

Comments: Population: Caucasian., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U-87MG ATCC

Synonyms: U-87MG, U-87 MG, U87 MG, U-87-MG, U87-MG, U87MG, U-87, U87, 87 MG, 87MG

Cross References: BTO:BTO_0002036, CLO:CLO_0009463, CLO:CLO_0009464, EFO:EFO_0005237, MCCL:MCC:0000469, CLDB:cl4592, CLDB:cl4594, CLDB:cl4595, CLDB:cl7166, Abcam:ab278079, AddexBio:C0005002/71, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-14, BCRC:60360, BCRJ:0241, BEI_Resources:ARP-2188, BioGRID_ORCS_Cell_line:348, BioSample:SAMN03472715, BioSample:SAMN03473126, BioSample:SAMN05292456, BioSample:SAMN07710026, BioSample:SAMN07710027, BioSample:SAMN07710028, BioSample:SAMN07710029, BioSample:SAMN07710030, BioSample:SAMN07710031, BioSample:SAMN07710032, BioSample:SAMN10988360, cancercellines:CVCL_0022, CCRID:1101HUM-PUMC000208, CCRID:3101HUMTCHu138, CCTCC:GDC0157, Cell_Model_Passport:SIDM01189, CGH-DB:157-1, ChEMBL-Cells:ChEMBL3307575, ChEMBL-Cells:ChEMBL3989361, ChEMBL-Targets:ChEMBL614247, CLS:300367, Cosmic:687590, Cosmic:849853, Cosmic:850741, Cosmic:850822, Cosmic:920816, Cosmic:1036336, Cosmic:1064099, Cosmic:1066234, Cosmic:1171224, Cosmic:1175825, Cosmic:1198263, Cosmic:1217671, Cosmic:1219449, Cosmic:1237542, Cosmic:1294951, Cosmic:1610737, Cosmic:1746951, Cosmic:1945859, Cosmic:2302316, Cosmic:2367555, Cosmic:2491106, Cosmic:2516044, Cosmic:2550364, Cosmic:2568870, Cosmic:2580918, Cosmic:2701083, Cosmic-CLP:687590, DepMap:ACH-000075, ECACC:89081402, EGA:EGAS00001000978, ENCODE:ENCBS424ENC, GDSC:687590, GEO:GSM101676, GEO:GSM101686, GEO:GSM101687, GEO:GSM101688, GEO:GSM326243, GEO:GSM481417, GEO:GSM500897, GEO:GSM887723, GEO:GSM888817, GEO:GSM923437, GEO:GSM1374974, GEO:GSM1638668, GEO:GSM1670559, GEO:GSM2113436, GEO:GSM2113437, GEO:GSM2113438, GEO:GSM2113439, GEO:GSM7701418, GEO:GSM7701419, IARC_TP53:21096, IBRC:C10982, ICLC:HTL00013, IZSLER:BS TCL 189, KCB:KCB 2011101YJ, KCLB:30014, LiGeA:CCLE_552, LINCS_HMS:50868, LINCS_LDP:LCL-1364, Lonza:37, Lonza:808, MetaboLights:MTBLS4708, MetaboLights:MTBLS6212, NCBI_Iran:C531, PharmacDB:U87MG_1623_2019, PRIDE:PXD000589, PRIDE:PXD000661, PRIDE:PXD001565, PRIDE:PXD003790, Progenetix:CVCL_0022, PubChem_Cell_line:CVCL_0022, RCB:RCB0419, TOKU-E:3381, Ubigen:YC-C028, Wikidata:Q7863603

ID: CVCL_0022

Record Creation Time: 20220427T221639+0000

Record Last Update: 20260905T182615+0000

Ratings and Alerts

No rating or validation information has been found for U-87MG ATCC.

Warning: Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in

PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknown. See U-87MG Uppsala (CVCL_GP63) for the original U-87MG cell line.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00535.

Population: Caucasian., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknown. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line.. **Warning:** Discontinued: RCB; RCB0419

Population: Caucasian., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknown. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3470 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Dolci S, et al. (2026) Tumor-associated macrophages enhance peripheral nerve tumor infiltration and spinal cord repair. *Immunity*, 59(2), 438.

de Gooijer MC, et al. (2026) Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma. *Cellular oncology (Dordrecht, Netherlands)*, 49(2), 46.

Wang Y, et al. (2026) Metabolic reinvigoration of NK cells by IL-21 enhances immunotherapy against MHC class I-deficient solid tumors. *Cell reports*, 45(3), 117035.

Pineau D, et al. (2026) EDNRB-dependent endothelin signaling reduces proliferation and promotes proneural-to-mesenchymal transition in gliomas. *Molecular oncology*.

Lu B, et al. (2026) Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma. *Cell death & disease*, 17(1).

Dai W, et al. (2026) An IGF2BP3-dependent metabolic circuit governs macrophage recruitment and immunosuppression in glioblastoma. *Cell reports*, 45(7), 117643.

Yang X, et al. (2026) Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging. *Journal of medicinal chemistry*, 69(14), 17054.

Abdi K, et al. (2026) miR-132 overexpression is associated with modulation in miR-21 expression and glioblastoma cell behavior. *PloS one*, 21(7), e0352119.

Lan TH, et al. (2026) A single-component optogenetic toolkit for reversible visualization and programmable control of microtubule dynamics. *Cell reports methods*, 101532.

Tao F, et al. (2026) An atom-edged magnetic nanomotor for cancer mechanotherapy. *iScience*, 29(3), 114994.

Zhao K, et al. (2026) Aromatic amino acid metabolism shapes autophagy-mediated adaptation to iron deprivation in glioblastoma cells. *Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine*, 39(3), 1167.

Yang F, et al. (2026) SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment. *Neoplasia (New York, N.Y.)*, 73, 101288.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Cheng M, et al. (2026) YTHDF3 facilitates DNA damage response by recognizing METTL3-mediated m6A modification to promote chemotherapy resistance in glioblastoma. *Cancer letters*, 649, 218445.

Rurka P, et al. (2026) A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. *Molecular oncology*.

Oksal MD, et al. (2026) IDH1 mutation promotes angiogenesis via upregulation of hypoxia inducible factor 1 alpha in glial tumors. *Mutation research*, 833, 111939.

Krygier K, et al. (2026) A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour-targeting function. *British journal of pharmacology*.

Huang Y, et al. (2026) Mechanosensation promotes broad-spectrum antiviral defense through membrane remodeling. *Cell chemical biology*, 33(3), 307.

Zhu M, et al. (2026) Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunity. *Biochemical pharmacology*, 246, 117721.

Jin Z, et al. (2026) Novel Covalent FAP-Targeted [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 for Improved Pharmacokinetics and Enhanced Tumor Uptake. *Molecular pharmaceutics*, 23(6), 3468.